Develops medicines for autoimmune and rare diseases, including treatments for thyroid eye disease and antibody-based therapies for other autoimmune disorders.
10-K for FY2025, filed Feb 26, 2026
Its business customers are companies that license rights to product candidates or work with Viridian on research and development; its future medicines are intended for patients with autoimmune and rare diseases.
10-K for FY2025, filed Feb 26, 2026
No. It lost $342.6M in FY2025.
10-Q for Q3 FY2026, filed Nov 4, 2026
−$101.2MView ↗
10-Q for Q3 FY2026, filed Nov 4, 2026
Open tableView ↗
8-K, filed Nov 9, 2026
In the trial, VRDN-008 demonstrated deep and sustained Immunoglobin G (“IgG”) reduction through eight weeks after subcutaneous dosing in…View ↗
8-K, filed Jun 29, 2026
On June 26, 2026, the Company announced that the FDA has approved Lumvoa™ (veligrotug-vvze) for the treatment of TED regardless of activity…View ↗
From development to commercialization
The older report described Viridian as discovering and developing medicines; the latest report adds commercialization and says the company is preparing its sales, market access, patient services, and commercial operations.
10-K for FY2022, filed Mar 9, 2023 10-K for FY2025, filed Feb 26, 2026We are a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases.…View ↗
Expanded disease programs
The older report centered on thyroid eye disease and described other rare-disease programs without naming their targets; the latest report also describes FcRn inhibitors for autoimmune disorders and a TSHR program for thyroid eye disease and Graves’ disease.
10-K for FY2022, filed Mar 9, 2023 10-K for FY2025, filed Feb 26, 2026Our pipeline targets validated pathways and disease-driving mechanisms in autoimmune and rare diseases. These include product candidates…View ↗
We are also developing a portfolio of engineered FcRn inhibitors, including VRDN-006 and VRDN-008. FcRn inhibitors have the potential to…View ↗
In January 2026, we announced that we are developing an anti-TSHR candidate with potential use in the treatment of Graves’ disease and TED.…View ↗
Competes with Amgen, Immunovant, Roche, Sling Therapeutics, Novartis, Lassen Therapeutics, Alumis, Argenx, UCB, Johnson and Johnson, GenSci, and AV7
10-K for FY2025, filed Feb 26, 2026Amgen’s Tepezza is the only FDA-approved medication for TED. Other therapies, such as corticosteroids, have been used on an off-label basis…View ↗
Loading...